- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PARDES BIOSCIENCES Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 82,50 | -0,60 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer | MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 133,00 | +0,76 % | Palvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer | Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 83,50 | -1,18 % | Dianthus Therapeutics: Kurseinbruch nach C1-Rückschlag - warum der Bullen-Case jetzt an Stärke gewinnt | Dianthus Therapeutics hat nach einem Rückschlag im C1-Inhibitor-Programm für HAE einen massiven Kursrückgang verzeichnet, der die Bewertung deutlich unter das aus fundamentaler Sicht gerechtfertigte... ► Artikel lesen | |
| LENZ THERAPEUTICS | 4,125 | -0,12 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple... ► Artikel lesen | |
| SPYRE THERAPEUTICS | 81,50 | +1,24 % | Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing... ► Artikel lesen | |
| LIANBIO | - | - | LianMedical (Formerly Known as LianBio) Announces Completion of Merger Between LianBio and LianMedical | • Combined company to operate as LianMedical
• LianMedical to focus on advancing patient access to innovative medical technologies in China and other Asia Pacific markets
PRINCETON, N.J. & SHANGHAI--(BUSINESS... ► Artikel lesen | |
| CG ONCOLOGY | 77,74 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,560 | +0,12 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,74 % | Qiagen sorgt für Gesprächsstoff, Rheinmetall bleibt unter Druck, Nvidia zeigt sich freundlicher und Siemens Energy profitiert von neuer Zuversicht im KI-Segment | Die Zinserhöhung der Fed sowie die Aussicht auf weitere Zinsschritte in der nahen Zukunft scheinen die Märkte erstaunlich schnell verdaut zu haben. Statt weiterer Kursstürze gab es am Donnerstag dann... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,780 | 0,00 % | Arcutis auf Morgan Stanley Konferenz: ZORYVE treibt Wachstumsoffensive voran | ||
| DECOY THERAPEUTICS | 3,100 | 0,00 % | Decoy Therapeutics, Inc: Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding | Next-Generation D-MAVs Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility
... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,050 | 0,00 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| AMYLYX PHARMACEUTICALS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 300,95 | +0,10 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 41,530 | 0,00 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen |
PARDES BIOSCIENCES INC gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PARDES BIOSCIENCES INC finden Sie auf Wallstreet Online.